Aclaris Therapeutics (ACRS) Retained Earnings (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Retained Earnings of -$987.6 million for Q1 2026, down 193.03% year-over-year from $1.1 billion in Q1 2025, and down 2.05% quarter-over-quarter from -$967.8 million in Q4 2025.
Aclaris Therapeutics (ACRS) Retained Earnings (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Retained Earnings history runs 13 years deep, the most recent figure standing at -$987.6 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 193.03% year-over-year to -$987.6 million; the TTM figure through Mar 2026 stood at -$987.6 million (down 193.03% YoY), while the FY2025 annual figure was -$967.8 million, down 997815.46% from the prior year.
- Retained Earnings for Q1 2026 stood at -$987.6 million, down from -$967.8 million in the prior quarter.
- The five-year high for Retained Earnings was $1.1 billion in Q2 2025, with the low at -$987.6 million in Q1 2026.
- The 5-year median for Retained Earnings is -$1.1 million (2023), against an average of -$47.5 million.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings jumped 103564.88% in 2023, then slumped 997815.46% in 2025.
- Aclaris Therapeutics' Retained Earnings stood at -$897000.0 in 2022, then surged by 103564.88% to $928.1 million in 2023, then plunged by 99.99% to $97000.0 in 2024, then plunged by 997815.46% to -$967.8 million in 2025, then slipped by 2.05% to -$987.6 million in 2026.
- Business Quant data shows ACRS's Retained Earnings at -$987.6 million in Q1 2026, -$967.8 million in Q4 2025, and -$948.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 1.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.13 Bn |
| Mar 31, 2026 | -987.61 Mn |
| Dec 31, 2025 | -967.78 Mn |
| Sep 30, 2025 | -948.00 Mn |
| Jun 30, 2025 | 1.06 Bn |
| Mar 31, 2025 | 1.06 Bn |
| Dec 31, 2024 | 97,000.00 |
| Sep 30, 2024 | -806.30 Mn |
| Jun 30, 2024 | -798.72 Mn |
| Mar 31, 2024 | -787.74 Mn |
| Dec 31, 2023 | 928.08 Mn |
| Sep 30, 2023 | -1.13 Mn |
| Jun 30, 2023 | 920.90 Mn |
| Mar 31, 2023 | 887.64 Mn |
| Dec 31, 2022 | -897,000.00 |
| Sep 30, 2022 | 875.98 Mn |
| Jun 30, 2022 | -634.73 Mn |
| Mar 31, 2022 | -614.20 Mn |
| Dec 31, 2021 | -224,000.00 |
| Sep 30, 2021 | -572.60 Mn |